NCT05830799View on ClinicalTrials.gov

A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Drug Interaction
Interventions
DRUG

Drug Drug Interaction

The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated

Trial Locations (1)

SE-752 37

CTC Clinical Trial Consultants AB, Uppsala

All Listed Sponsors
lead

Vicore Pharma AB

INDUSTRY